BCTXW (BriaCell Therapeutics) Other Stockholders Equity: $41.42 Mil (As of Apr. 2026)


BCTXW BriaCell Therapeutics Corp BCTXW
23 GF Score
Price $0.00
! 2 Warning Signs
View Full Analysis

What is BriaCell Therapeutics Other Stockholders Equity?

BriaCell Therapeutics BCTXW 23 Other Stockholders Equity is $41.42 Mil as of Apr. 2026. GuruFocus rates BCTXW with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

BriaCell Therapeutics's Other Stockholders Equity for the quarter that ended in Apr. 2026 was $41.42 Mil.

BriaCell Therapeutics's quarterly Other Stockholders Equity increased from Oct. 2025 ($28.33 Mil) to Jan. 2026 ($41.11 Mil) and increased from Jan. 2026 ($41.11 Mil) to Apr. 2026 ($41.42 Mil).

BriaCell Therapeutics's annual Other Stockholders Equity increased from Jul. 2023 ($7.42 Mil) to Jul. 2024 ($11.04 Mil) and increased from Jul. 2024 ($11.04 Mil) to Jul. 2025 ($28.04 Mil).

BriaCell Therapeutics Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for BriaCell Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BriaCell Therapeutics Other Stockholders Equity Chart

BriaCell Therapeutics Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 7.42 11.04 28.04

BriaCell Therapeutics Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.20 28.04 28.33 41.11 41.42
BCTXW
23GF Score
BriaCell Therapeutics Corp BCTXW
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BriaCell Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $41.42 Mil mean?
BriaCell Therapeutics (BCTXW) has a Other Stockholders Equity of $41.42 Mil as of Apr. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on BriaCell Therapeutics and its competitors.
Is BriaCell Therapeutics' Other Stockholders Equity too high?
BriaCell Therapeutics' current Other Stockholders Equity is $41.42 Mil. Overall, BriaCell Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does BriaCell Therapeutics' Other Stockholders Equity compare to VRTX and REGN?
BriaCell Therapeutics' Other Stockholders Equity of $41.42 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on BriaCell Therapeutics and its competitors. BriaCell Therapeutics's current Other Stockholders Equity is $41.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BriaCell Therapeutics stock overvalued right now?
BriaCell Therapeutics (BCTXW) has a current Other Stockholders Equity of $41.42 Mil. The current Other Stockholders Equity is $41.42 Mil. BriaCell Therapeutics' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For BriaCell Therapeutics (BCTXW), the current Other Stockholders Equity is $41.42 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BriaCell Therapeutics Business Description

Address 235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
23GF Score

Get the complete analysis for BCTXW

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price